In a presentation at JPMorgan’s healthcare investment conference in San Francisco late Monday, Merck executives presented a rosy picture as the company heads toward the 2028 patent expiration.

The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

a professor at UC Law San Francisco. Such heightened risk could lead vaccine makers to raise prices or pull a product off the market, said John Grabenstein, a consultant and former Merck vaccine ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously ... Davis on Monday at the JPMorgan Healthcare Conference in San Francisco. "That's actually new information and an acceleration from ...

Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Following Merck announcing their goal to phase out ... At the 8th Annual Tumor Models San Francisco Summit, you will gain practical insights into the latest updates across the West Coast and ...

Merck CEO Rob Davis told CNBC's Jim Cramer that ... Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News Headlines newsletter. He also pointed ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...